Clinical Trials

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

USA
Connecticut
New Haven

This is a Phase II clinical trial aimed at treating patients with T-cell lymphomas (T-cell blood cancers). The drug consists of a toxin, called diphtheria toxin, which is attached to an antibody that can specifically target cancerous T-cells. Our primary objectives are, therefore, to determine the patient subgroup with respect to disease burden who best responds to this experimental drug in treating CD3 positive T cell malignancies. We will be determining how the patient and their disease respond to this research agent.

For more information: http://clinicaltrials.gov/ct2/show/study/NCT00611208?view=record

Travel & Lodging Defrayment
As a result of study participation, travel will be requested to a participating medical center. Angimmune (the study sponsor) will partially pay to defray travel & lodging costs for a family member to accompany a patient to this trial. Please contact the appropriate Clinical Research Coordinator at the trial site listed below for more information.

Yale Cancer Center
Yale University School Of Medicine Recruiting  -  Recruiting
New Haven, Connecticut, United States, 06520
Contact: Francine Foss, MD    203-737-5312      
Contact: Diana Irizarry, RN    (203) 737-2451    diana.irizarry@yale.edu   
Principal Investigator: Francine M. Foss, MD         
Sub-Investigator: Terri L Parker, MD         
Sub-Investigator: Stuart E Seropian, MD  

Link: http://medicine.yale.edu/cancer/patient/trials/available/OnCore1207010601.trial